Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

被引:228
作者
Mulvihlll, S
Warren, R
Venook, A
Adler, A
Randlev, B
Heise, C
Kirn, D
机构
[1] Hammersmith Hosp, Imperial Canc Res Fund, Imperial Coll,Sch Med, Mol Oncol Unit,Viral & Genet Therapy Program, London W12 0HS, England
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[4] Onyx Pharmaceut, Richmond, CA USA
关键词
adenovirus; replication-selective; oncolytic virus; pancreatic cancer; phase I clinical trial;
D O I
10.1038/sj.gt.3301398
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Novel therapies are needed for locally advanced pancreatic carcinoma. ONYX-015 (dl1520) is an E1B-55 kDa region-deleted adenovirus that selectively replicates in and lyses tumor cells with abnormalities in p53 function leg gene mutation). We carried out a phase I dose escalation study of ONYX-015 in patients with unresectable pancreatic cancer. ONYX-015 was administered via CT-guided injection (n = 22 patients) or intraoperative injection (n = 1) into pancreatic primary tumors every 4 weeks until tumor progression. Interpatient dose escalation was carried out with at least three patients per dose level from 10(8) p.i.u. up to the 10(11) p.f.u. dose level (two patients treated at this dose). The majority of patients had abnormally low cellular immunity (CD4 counts and hypersensitivity skin testing). Injection of ONYX-015 into pancreatic carcinomas was well-tolerated. Mild, transient pancreatitis was noted in only one patient. Dose-escalation proceeded to the highest dose level. Neutralizing antibodies rose post-treatment in all patients. After injection, ONYX-015 was detectable in the blood 15 min later, but not between 1 and 15 days later. Viral replication was not documented, however, in contrast to trials in other tumor types. No objective responses were demonstrated Intratumoral injection of an E1B-55 kDa region-deleted adenovirus into primary pancreatic tumors was feasible and well-tolerated at doses up to 10(11) p.f.u. (2 x 10(12) particles), but viral replication was not detectable.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 26 条
[1]  
ABBRUZZESE J, 1997, CANC PRINCIPLES PRAC, P1054
[2]   ADENOVIRUS PROTEINS FROM BOTH E1B READING FRAMES ARE REQUIRED FOR TRANSFORMATION OF RODENT CELLS BY VIRAL-INFECTION AND DNA TRANSFECTION [J].
BARKER, DD ;
BERK, AJ .
VIROLOGY, 1987, 156 (01) :107-121
[3]   ABNORMALITIES OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN PANCREATIC-CANCER [J].
BARTON, CM ;
STADDON, SL ;
HUGHES, CM ;
HALL, PA ;
OSULLIVAN, C ;
KLOPPEL, G ;
THEIS, B ;
RUSSELL, RCG ;
NEOPTOLEMOS, J ;
WILLIAMSON, RCN ;
LANE, DP ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1076-1082
[4]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
[5]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[6]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[7]   IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY [J].
CHANG, FJ ;
SYRJANEN, S ;
SYRJANEN, K .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :1009-1022
[8]   ABLATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES TRANSGENE PERSISTENCE AND DECREASES INFLAMMATORY RESPONSE IN MOUSE-LIVER [J].
ENGELHARDT, JF ;
YE, XH ;
DORANZ, B ;
WILSON, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :6196-6200
[9]  
Ganly I, 2000, CLIN CANCER RES, V6, P798
[10]   ROLE OF EARLY REGION-3 (E3) IN PATHOGENESIS OF ADENOVIRUS DISEASE [J].
GINSBERG, HS ;
LUNDHOLMBEAUCHAMP, U ;
HORSWOOD, RL ;
PERNIS, B ;
WOLD, WSM ;
CHANOCK, RM ;
PRINCE, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3823-3827